--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-268698" form_type: "8-K" ticker: null cik: "0001531048" company_name: "Inari Medical, Inc." filed_at: "2023-11-02T23:59:59+00:00" generated_at: "2026-06-09T00:08:17.363664+00:00" event_type: "m_and_a" sentiment: "positive" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Inari Medical to acquire LimFlow for $250M cash, plus up to $165M in milestones ## Summary - Upfront purchase price of $250M in cash; contingent payments up to $165M based on commercial and reimbursement milestones. - LimFlow's TADV system received FDA approval in Sept. 2023; targets no-option CLTI patients facing amputation. - Transaction expected to close in Q4 2023; financed with cash on hand and borrowings under expanded credit facility. - Credit facility amended: revolver increased from $40M to $75M; BSBY rate + 1.60%-2.10% margin for new loans. - Inari sees CLTI as a $1.5B annual U.S. opportunity; conservative estimate of 55,000 treatable patients per year. ## SEC filing metadata - accession: 0001193125-23-268698 - form_type: 8-K - cik: 0001531048 - company_name: Inari Medical, Inc. - filed_at: 2023-11-02T23:59:59+00:00 - event_type: m_and_a - sentiment: positive - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 1.01, 2.03, 7.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/d561000d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-268698 - JSON: https://secwatch.observer/filing/0001193125-23-268698.json - Plain text: https://secwatch.observer/filing/0001193125-23-268698.txt ## Key facts - Debt Financings Inari Medical, Inc. amended revolving credit of from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amo with Bank of America, N.A. at BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that range. - Instrument: revolving credit - Principal: from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amo - Counterparty: Bank of America, N.A. - Rate: BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that range - Event: amendment source text: The Amendment, among other things, (i) increases the amount available under the revolving credit facility from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amount of the borrowing base, (ii) provides that advances under the Amended Credit Agreement will bear interest at a rate per annum equal to the BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that ranges from 0.60% to 1.10% in the case of Base Rate loans and 1.60% to 2.10% in the case of BSBY Rate loans depending on average daily availability, in each case with a floor of 0%, (iii) increases the letter of credit subline from $10.0 million to $18.75 million evidence_url: https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm - Material Agreements Inari Medical, Inc. entered into Share Purchase Agreement with LimFlow S.A. valued at Initial purchase price of $250,000,000, plus contingent payments up to $165,000,000 (effective 2023-10-31). - Action: entry - Agreement: merger - Counterparty: LimFlow S.A. - Value: Initial purchase price of $250,000,000, plus contingent payments up to $165,000,000 - Effective: 2023-10-31 source text: On October 31, 2023, Lombardi Sub, LLC, a Delaware limited liability company (the “ Purchaser ”) and an indirect wholly-owned subsidiary of Inari Medical, Inc. (the “ Company ”, “ we ” or “ us ”), the Company, as guarantor of Purchaser’s financial obligations, LimFlow S.A., a French limited liability company (société anonyme) (“ LimFlow ”), equity holders of LimFlow (the “ Sellers ”) and Shareholder Representative Services LLC, a Colorado limited liability company (the “ Seller Representative ”), entered into a Share Purchase Agreement (the “ Purchase Agreement ”). evidence_url: https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm - Material Agreements Inari Medical, Inc. amended Amendment to Loan, Guaranty and Security Agreement with Bank of America, N.A. and other lenders valued at Increased revolving credit facility from lesser of $40.0 million and borrowing base to lesser of $75 (effective 2023-11-01). - Action: amendment - Agreement: credit facility - Counterparty: Bank of America, N.A. and other lenders - Value: Increased revolving credit facility from lesser of $40.0 million and borrowing base to lesser of $75 - Effective: 2023-11-01 source text: On November 1, 2023, the Company, Inari Medical International, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Inari Medical Latin America, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, each of the lenders signatory thereto (the “ Lenders ”) and Bank of America, N.A. (as the agent for the Lenders, the “ Agent ”) entered into an amendment (the “ Amendment ”) to the Loan, Guaranty and Security Agreement, dated as of September 4, 2020 evidence_url: https://www.sec.gov/Archives/edgar/data/1531048/000119312523268698/0001193125-23-268698-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.